pancreatic cancer pancreatic ductal adenocarcinoma
Conditions
Interventions
Whole blood will be collected from 100 pancreatic cancer patients. A small part
of tumor will be stored for analysis from patients who will undergo a resection.
During the course of the study blood
Sponsors
Stichting Leveronderzoek
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Age >= 18 years • Diagnosed with resectable or borderline resectable pancreatic cancer, locally advanced pancreatic cancer or metastasized pancreatic cancer • Planned treatment with either currently available standard of care treatments for pancreatic cancer (e.g. surgery, gemcitabine, neoadjuvant chemoradiotherapy, FOLFIRINOX and/or (stereotactic) radiotherapy) or new treatment options such as, but not limited to, Ampligen® (immunotherapy) or DC therapy. • Signed informed consent
Exclusion criteria
Exclusion criteria: • Unable to draw blood for study purposes • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • To determine the baseline immune signature in pancreatic cancer patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| • To investigate whether the immune profile found in the PB reflects the local immune signature of the pancreatic tumor. • To monitor the effect of treatment (neoadjuvant CRTx, adjuvant chemotherapy or palliative chemotherapy) on the expression of co-inhibitory molecules and their ligands on TIL and PB lymphocytes. | — |
Countries
Netherlands
Outcome results
None listed